Urology Times staff

“PSMA-PET imaging gives us a more nuanced approach by giving us more accurate information,” says Jen-Jane Liu, MD.

"We have become more advanced over time. We understand that men's health is more than just testosterone. Men's health is more than just erectile function and prostate disease," says Michael D. Lutz, MD.

Jen-Jane Liu, MD, discusses how PSMA-PET imaging might help physicians decide whether or not a patient with prostate cancer needs lymph node dissection.

“We need to experience fairness and respect, and we need to see that our individual values align with the values of our organizations, and of our health care system as a whole,” says Colin P. West, MD, PhD.

"What we found is that AI+ score using continuous variables had the highest predictive ability of all oncologic outcomes that were measured," says Nour Abdallah, MD.

"A lot to be done in terms of moving PARP inhibitors earlier. Is that safe? Where do we get the most bang for our buck? And does the therapy have to be indefinite?" says Ashley E. Ross, MD, PhD.

“To convince the doctors pre pandemic of telemedicine was pretty difficult, but now we know that telemedicine works and the physicians are embracing it,” says Lisa J. Finkelstein, DO, FACOS.

"This study looks at comparing BCG, which is our classic mainstay in the treatment of high-risk non-muscle–invasive bladder cancer to intravesical gemcitabine-docetaxel," says Diana Magee, MD.

"When it comes to BPH therapy, we've seen a lot of innovation when it comes to the therapeutics; the diagnostics have been a tiny bit behind," says Bilal Chughtai, MD.

“We need to continue to advocate for the patient,” says Arthur L. Burnett II, MD, MBA.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

“Resilience isn't just about being able to bounce back; it's about being able to bounce back better,” says Colin P. West, MD, PhD.

"Because we don't have calibration data on Black, or Hispanic, or Asian men in many of these risk tools, we don't know the impact of these tools as screening tests," says Adam Murphy, MD, MBA, MSCI.

“I think, overall, nomograms are a really powerful tools just because there are so many different clinical variables that we consider when we talk to patients about whether to proceed with prostate biopsy,” says Eric Li, MD.

“There really is a significant lack in sexual medicine research of cost information, care information, [and] outcomes information,” says Martin S. Gross, MD.

Vivally System is a neuromodulation system that uses a closed-loop control algorithm and electromyography to personalize treatment for each patient.

“The cost and the burden of being able to find permissions and licenses within different states to continue to offer these services once the waivers end will essentially negate all of these services,” says Kara L. Watts, MD.

“Patients are paying humongous amounts of money to get pills that are essentially very, very, very cheap,” says Faysal A. Yafi, MD, FRCSC.

"After 6 months, about 77% of this group have more than 50% improvement on their main symptom," says John Heesakkers, MD, PhD.

“I think there's a mindset out there that you have to have experienced a particular mental health crisis or some other major sort of breaking point event in your medical career. That's not actually my story,” says Colin P. West, MD, PhD.

“Remote supervision is something that we are utilizing now and look forward to even growing further,” says Lisa J. Finkelstein, DO, FACOS.

“I would classify hidden burdens as things which we don't appreciate on the surface, or that aren't obvious that are associated with erectile dysfunction,” says John J. Mulcahy, MD, PhD.

"The hazard ratio was 0.42, which is a 58% reduction of an MFS event in favor of the combination arm," says Neal D. Shore, MD, FACS.

"We found that in the 25-patient pilot study that we did, that the accuracy was about 98% of what a standard sequencer would offer," says Deepak Kapoor, MD.

The update was presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois.

"Among the 76 men–who had an average age of about 70 and a PSA value of 4.4–up to 99% of them were able to find recurrent cancers," says Brian Helfand, MD, PhD.

"What we noticed is that even though it's not in the NCCN guidelines, a lot of urologists are using oral Relugolix in combination with other prostate cancer medications in similar numbers to the injectables," says Jason M. Hafron, MD.

"Something that we did find that was more promising was that regardless of whether a patient did or did not have a mental health disorder diagnosis, that did not affect their rate of receiving gender-affirming medical therapy," says Helen Sun, MD.

"We found that on average, [a] patient went into surgery with a GFR of about 55, and came out with a GFR of about 44," says Steven Campbell, MD, PhD.

"Overall, we found that Prostate Health Index above 55 preoperatively was associated with any incidental prostate cancer as well as clinically significant prostate cancer," says Eric Li, MD.